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Abstract
Background: The outgrowth of new vessels – angiogenesis – in the tumour mass is considered
to be a limiting factor of tumour growth. To inhibit the matrix lysis that is part of the tumour
angiogenesis, we employed the chimeric protein mhATF-BPTI, composed of the receptor binding
part of the urokinase (ATF) linked to an inhibitor of plasmin (BPTI).
Methods: For delivery, recombinant adenovirus encoding the transgene of interest was injected
intravenously or locally into the tumour. The anti tumour effect of this compound was compared
to that of human endostatin and of mhATF alone in two different rat bronchial carcinomas growing
either as subcutaneous implants or as metastases.
Results: Significant inhibition of the tumour growth and decrease of the number of lung metastasis
was achieved when the concentration of mhATF-BPTI at the tumour site was above 400 of ng / g
tissue. This concentration could be achieved via production by the liver, only if permissive to the
recombinant adenovirus. When the tumour cells could be transduced, local delivery of the vector
was enough to obtain a response. In the case of metastasis, the capacity of the lung tissue to
concentrate the encoded protein was essential to reach the required therapeutic levels. Further,
endostatin or mhATF could not reproduce the effects of mhATF-BPTI, at similar concentrations
(mhATF) and even at 10-fold higher concentration (endostatin).
Conclusion: The ATF-BPTI was shown to inhibit tumour growth of different rat lung tumours
when critical concentration was reached. In these tumour models, endostatin or ATF induce
almost no tumour response.
Background
It has been suggested that solid tumours can not grow be-
yond 60–80 cells without inducing the formation of new
blood vessels: tumour angiogenesis [1]. This blood vessel
formation requires proliferation of endothelial cells, cell
migration and the lysis of the different components of the
matrix (collagen, elastin, fibronectin) by several proteas-
es. One of great importance, urokinase (uPA) and its high
affinity receptor, the GPI-anchored membrane CD87 (uP-
AR), is critical in tumour progression and its level of ex-
pression is correlated with poor prognosis of various
cancers such as prostate [2], breast [3], colon [4], ovarian
[5], gastric [6], brain [7], and lung cancer [8]. Urokinase
(uPA) and its main product plasmin belong to the very
early proteases [9–11] that activate the metallo-protease
(MMP) cascade and therefore control cell motility, tissue
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remodelling and the activation of various angiogenic fac-
tors (VEGF, TGFβ). Most of these proteases (e.g. uPA) are
localised at the tumour site through receptors that are
highly expressed on the surface of activated endothelial
cells and tumour cells. A high level of uPAR at the invasive
edge of the tumour concentrates uPA where neoangiogen-
esis occurs [12], generating the full activation of the MMP
cascade [13]. Furthermore, various cellular migrations
proceed upon the transient attachment of the uPAR to
matrix components (e.g. vitronectin) [14], and uPA as
well as plasmin activate angiogenic factors such as VEGF,
HGF, FGFs, and TGFβ [15–17].
The inhibitors of the matrix lysis can be divided in two
categories: the synthetic inhibitors and the endogenous
ones. Most of the synthetic inhibitors are competitive in-
hibitors of the metallo-proteases, mimicking the substrate
of the enzymes (marismatat and derivatives). The endog-
enous inhibitors (e.g. endostatin, angiostatin, throm-
bospondin) differ in their angiostatic activity from
synthetic inhibitors, since they appear to also block en-
dothelial cell proliferation and/or migration. In this paper
we described the antitumour effects of a hybrid protein,
consisting of the Amino Terminal Fragment linked to Bo-
vine Pancreatic Trypsin Inhibitor (ATF-BPTI), delivered by
gene therapy with adenoviral vector.
ATF is the N-terminal part of the uPA (residues 1–135)
that binds to the uPA receptor (uPAR) and thus inhibits
the formation of the uPA-uPAR complex. Systemic and lo-
cal delivery of an adenovirus encoding ATF have been
shown to inhibit the growth of primary tumour implants
as well as of tumour metastasis in different animal models
[18,19]. In the ATF-BPTI chimeric protein, ATF has two
functions (1) the anti uPA effect with its known angiostat-
ic activity and (2) delivery of BPTI at the tumour site due
to over-expression of uPAR on tumour and endothelial
cells. The ATF is species specific between the human and
the mouse [20] and is not specific between the mouse and
the rat. The murinised version of ATF-BPTI differs by four
amino acids from the human version It was shown to
bind to the rat receptor and to inhibit plasmin activity in
a rat model [21]. BPTI (commercialised as aprotinin) is a
serine protease inhibitor prepared from bovine lung tissue
which dose dependently inhibits human trypsin, plasmin
and kallikrein. Aprotinin acts in a number of interrelated
ways to provide an anti-fibrinolytic effect. Thus, aprotinin
is mainly used in the clinic as anti-haemorrhagic agent in
extracorporal circulation (valve replacement, coronary by-
pass), for preventing postoperative haemorrhage, and as
anti protease in acute pancreatitis. BPTI has been used sys-
temically in a few animal tumour models, and showed
anti-tumour effects in a mouse hepatoma, lung carcino-
ma, and mammary carcinoma [22–24], and in a fibrosar-
coma of the hamster [24]. However, BPTI was not further
developed as a systemic anti tumour agent probably be-
cause of its anti fibrinolytic property that might preclude
its use in cancer patients. Its linkage to ATF is expected to
ameliorate or reduce that side effect.
In this study, the tumour growth inhibiting effect of ATF-
BPTI gene transfer was investigated and compared to en-
dostatin and ATF. The adenoviral vector was administered
intravenously, which leads to the ATF-BPTI production
and secretion by the liver, or by intra tumoral injection. In
the latter case, the protein is mostly produced by trans-
duced tumour cells. Two transplantable rat bronchial car-
cinomas, growing either as subcutaneous implants or as
lung metastasis were employed as targets. Levels of ATF-
BPTI in the plasma and in tissues were determined and the
association with tumour responses is described.
Methods
Animals
Pathogen-free inbred male Wag/Rij and Brown Norway
rats, weighing 300 to 350 gr were purchased from Harlan,
The Netherlands. All animals were fed ad libitum with
laboratory chow and water and were kept under standard
laboratory conditions. For assay of plasma hEndostatin,
and mhATF-BPTI, rats were anaesthetised with isoflurane
and bled by tail vein puncture and the blood was collected
in EDTA containing tubes. All animal procedures were
performed in accordance with the official guidelines after
obtaining permission of the animal welfare committee.
ATF-BPTI cloning
The plasmid encoding the ATF-BPTI (pAB) was provided
by P. Quax (TNO-PG, Leiden). The ATF plasmid was con-
structed by deleting the DNA sequences encoding amino
acids 139 to 401 of the urokinase cDNA plasmid. Then a
DNA fragment encoding the amino acids residues 36–96
of the bovine pancreatic trypsin inhibitor (BPTI) was
cloned into the ATF plasmid resulting in a plasmid encod-
ing the ATF, the BPTI and the 11 C-terminal amino acids
of urokinase including the stop codon. After sequence
confirmation, the ATF-BPTI cDNA was cloned into the re-
combinant adenovirus (Ad) shuttle vector Adapt. The
murinised ATF-BPTI (mhAB) plasmid was constructed by
an identical procedure, using the (Tyr22, Arg27,29,30)
uPA mutant cDNA as starting sequence [33].
Adenoviral vectors
Recombinant adenovirus vectors were generated in
PER.C6™ cells by homologous recombination between an
Adapter plasmid (pAdapt) and the E1 deleted Ad 5 DNA
plasmid as described elsewhere [34]. The expression cas-
sette contains a CMV promoter and SV40 poly A signal. As
a result of the absence of sequence overlap between the
Adapt plasmid and the Ad5 E1 sequences integrated into
the genome of PER.C6, the vector stocks used in this studyBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
Page 3 of 15
(page number not for citation purposes)
does not contain replicative competent adenovirus (RCA)
[35].
The Ad Adapt mhAB encodes for a murinised form of the
human ATF-BPTI [21]. In this construct the mhAB, is pre-
ceded by the native secretion signal peptide of the human
urokinase. The human endostatin coding sequence (Invi-
voGen, CA, USA) was cloned in the Ad Adapt shuttle vec-
tor. The encoded endostatin corresponds to the 183
residue of the human endostatin described by O'Reilly et
al (1997) with an intact N-terminus (HSHRDFQ...), pre-
ceded by the secretion signal peptide of the human IL-2.
The Ad.Adapt.Luc and the Ad.Adapt.LacZ are recom-
binant adenoviral vectors in which the E3 region of Ad5 is
retained and the gene of interest (luciferase or LacZ) re-
places the E1 region. The Ad Adapt empty is identical to
Ad Adapt mhAB except that it does not encode any trans-
gene.
All vectors were produced on PER.C6™ using standard
procedures [35]. Infectious units (iu) were determined by
end point cytopathogenic effect (CPE) assay on 911 cells
[36]. Viral particles were determined by HPLC [37]. The
particle to infectious unit ratio was always lower than 10.
Elisa and activity analysis
An mhATF-BPTI ELISA was developed by P. Quax et al
[21], using a monoclonal antibody specific for the ATF as
the capture antibody and a polyclonal antibody directed
against BPTI as the detector antibody. As a standard we
used urokinase or mhATF-BPTI. The biologic activity of
the mhATF-BPTI was tested in vitro in a plasmin inhibi-
tion assay using the chromogenic substrate S2251 (Chro-
mogenix, Mölndahl, Sweden). Diluted samples of Ad
Adapt mhAB infected A549 cells medium were incubated
for 15 min at room temperature with 200 pmol/l plasmin.
S251 was then added and after 24 hours incubation at 37
C the A405 was measured to determine the conversion of
the chromogenic substrate. Controls consisted of plasmin
solution incubated with buffer or with 1.0 KIU /ml apro-
tinin.
The human endostatin activity was tested in the human
umbilical vein endothelial cells HUVEC proliferation as-
say. In short, HeLa cells were incubated for 2 days with the
Ad Adapt human endostatin and the medium was collect-
ed. Fibroblast growth factor (bFGF)-stimulated HUVEC in
96 wells plate were incubated for 2 days with hEndostatin
infection medium. The proliferation of the HUVEC cell
was determined by measuring the incorporation of BrdU.
Levels of human endostatin in rat plasma was determined
with a human enzyme-linked immunoabsorbent assay
(ELISA) kit (InvivoGen, CA USA) according to the manu-
facturers procedure.
Tumour models
The L42 tumour is a bronchial squamous carcinoma that
originated in a Wag/Rij rat after intrapulmonary implan-
tation of an iodine-125 seed [38]. L44 adenocarcinoma
was induced in Brown Norway rats by local irradiation of
the thorax [39]. Both tumours are also adapted to cell cul-
ture and give rise to tumours with the same histological
characteristics as the original tumours. These two carcino-
mas were serially passaged in syngeneic rats for more than
50 passages. The CC531 tumour is a dimethylhydrazine-
induced, moderately differentiated colon adenocarcino-
ma exhibiting weak immunogenicity [40]. The tumour is
transplantable in syngeneic Wag/Rij rats. The subcutane-
ously growing tumour has a low microvascular density of
1.4% ± 0.6 (n = 10) and a volume doubling time of 10
days ± 0.8 (n = 10). For the experiments, the tumours were
established in the flank of rats by implanting small pieces
(3 × 3 × 3 mm) of tumour tissue sub-cutaneously as de-
scribed before [41].
The size of the subcutaneous tumours was measured in
three dimensions at regular intervals, using a Vernier cal-
liper. The volume of the tumours was calculated, from the
three tumour dimensions measures (a, b, c), with the for-
mula V = πabc/6. The doubling time of the different tu-
mours was calculated between volume of 1000 and 2000
mm3.
Microvascular density (MVD) in the L44, L42, and CC531
tumours was determined as follows: When the tumours
reached the size of 10 × 10 × 10 mm, the animals were sac-
rificed and frozen sections through the middle of the tu-
mours were prepared. We used an anti-mouse CD31
antibody (American Diagnostica), that cross reacts with
rat CD31, to stain specifically the endothelial cells that
can then be easily selected by the image analyser software
Qwin™. The software allowed us to quantify the surface of
the selected endothelial cells and to relate it to the surface
of non-necrotic tumour tissue. The end value is the surface
of all endothelial cells as percentage of the surface of non-
necrotic tissue: the microvascular density.
The global process including cell infection and protein
production is commonly called in the literature adenovi-
ral permissiveness. The in vitro permissiveness of the dif-
ferent cell lines to adenovirus was determined by
infection of the cells by graded MOI of Ad5 Adapt Luci-
ferase. The Luciferase activity was measured in the super-
natant of the cell culture lysate after 2 days of culture and
expressed in RLU / milligram of protein. The in vivo per-
missiveness of the tumours was assessed by analysing the
lysate of the whole tumour (without any surrounding tis-
sue) 2 days after injection of the Ad Adapt Luc. Adenoviral
vector was administered in a volume of 100 µL to 8 × 8 ×
8 mm tumours.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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For the metastases model the L44 and L42 cell lines were
cultured in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% FBS. When the cells
reached 80% of confluence, they were trypsinised, washed
and resuspended in PBS. 104 L44 tumour cells or 5.104
L42 tumour cells (0.5 ml) were injected into the tail vein
of the syngeneic rat. The animals were sacrificed after 22
days (L44 bearing Brown Norway) and 53 days (L42 bear-
ing Wag/Rij), the lungs fixed in Bouin solution and the
nodules on the surface were counted. The first experi-
ments, in which animals were not treated, showed that all
animals developed multiple metastases in the lungs. The
average number of nodules counted on the lung surface
was 58 in Wag/Rij and 93 in Brown Norway rats. The vol-
ume doubling time of the metastases in the lung was ex-
trapolated from the volumes determined at two time
points. The volume at 11 days (for the L44) and at 20 days
(for the L42) was determined by measuring the size of mi-
croscopic metastasis on lung sections (10 metastases per
rat, 4 rats per tumour model). The final volume of the
nodules on the lung surface was assessed, on day 22 for
the L44 and day 53 for the L42, using a Vernier calliper
(10 nodules per rat, 10 rats per tumour model).
Luciferase assays in tissues
Rats were sacrificed by an overdose of isoflurane and
whole organs were dissected out, frozen in liquid nitrogen
and stored at -80°. Organs were homogenised in phos-
phate buffered saline pH 7.8 using a blender. To lyse the
cells, DTT (SIGMA, The Netherlands) (1 mM) and Triton
x-100 (0.1%) (Merck, The Netherlands) were added. After
centrifugation at 10,000 rpm for 10 min, 20 µl of the su-
pernatant was added to 100 µl of luciferase assay substrate
(Promega, The Netherlands). Relative light units (RLU)
were determined for 30 s using a luminometer (Lumat
951, Wallac, Belgium). The amount of protein in the ex-
tracts was determined using a commercial kit (Bio-Rad
laboratories, The Netherlands) based on the Coomasie
brilliant blue G250 binding assay developed by Bradford
[42]. The level of luciferase activity in the tissue homoge-
nates was expressed in RLU / mg protein. The background
level of this assay is <1000 RLU/mg protein and was de-
fined by measuring luciferase activity in organs of non
treated rats.
mhATF-BPTI determination in tissues
Rats were sacrificed by an overdose of isoflurane and the
blood was flushed out by cutting the vena cava and inject-
ing 100 ml PBS into the right ventricle. The whole organs
or tumours were dissected out and weighted, frozen in liq-
uid nitrogen and stored at -80 C. Tissue and organs were
homogenised in phosphate buffer pH 7.8 using a blender.
To prepare a cell lysate, DTT (SIGMA, The Netherlands) (1
mM) and Triton x-100 (0.1%) (Merck, The Netherlands)
were added. After centrifugation at 10,000 rpm for 10
min, the ELISA was performed on 1:100 dilution of the
supernatant. Total protein in the extracts was determined
as described above. The concentration of mhATF-BPTI
was expressed in ng / g tissue. The background level of this
assay is < 20 ng / g tissue and was defined by measuring
the mhATF-BPTI in organs of rats treated with the empty
vector.
LacZ expression assay
Forty-eight hours after Ad.Adapt.LacZ administration rats
were sacrificed and organs were removed and cut in 2 mm
sections. Sections were fixed in 10% phosphate buffered
formalin (pH 7.0) for 60 min at room temperature and in-
cubated overnight in 0.5 M sucrose at 4°C. The samples
were subsequently frozen in liquid nitrogen. Ten micron
thick frozen sections were prepared and stained with 5-
bromo-4-chloro-3-indolyl-β-galactopyranoside (X-gal)
solution (Molecular Probes, The Netherlands) overnight
at 37 C. Finally, sections were counterstained with Hema-
toxylin-Phloxin-Safran.
Statistical analysis
Survival time until tumour size of 20 ml was analysed by
log range analysis of Kaplan-Meier curves. Analysis of var-
iance (ANOVA) was used to analyse the differences in tu-
mour growth delay. Scheffe's test was employed to analyse
the difference between the numbers of metastases, be-
tween plasma concentrations, and between MVDs.
Results
Tumour characteristics
Carcinomas of the lung were chosen, as it is the most fre-
quent tumour in the cancer population. Several vasculari-
sation phenotypes can be observed in the different
histological type of lung cancer. Therefore a bronchial sq-
uamous cell carcinoma and an adenocarcinoma with dif-
ferent microvascular density (MVD) were selected to
assess the inhibition effect of the ATF-BPTI. The growth
characteristics of the tumours are listed in Table 1. The
L44 adenocarcinoma grows roughly 2.5-fold faster than
the squamous cell carcinoma L42. This difference of
growth rate holds for in vitro culture of the cells as well as
for subcutaneous tumours and lung metastasis. Probably
related to the growth rate, the vascularisation of the L44
tumours was significantly higher (p < 0.001, Scheffe'test)
than that of the L42 tumours. The distribution of en-
dothelial cells in each of the tumour is homogeneous in
the viable part of the tumour. However, the L42 tumour
develops a necrotic area with no vessels in the centre of
the tumour mass as it grows above 8 × 8 × 8 mm.
The in vitro permissiveness to Ad5 of the cultured cell line
showed that the L42 carcinoma had a 2 log higher permis-
siveness than the L44 tumour (Fig 1A). These characteris-
tics are preserved in vivo when using the luciferase as wellBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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as the LacZ marker gene delivered in 10 × 10 × 10 mm tu-
mours. Luciferase activity, 2 days after intra tumoral injec-
tion of 1010iu Ad Adapt Luc, was 2 log higher in the L42
tumours than in the L44 adenocarcinoma (Fig 1B). The
luciferase activity in various organs of the Wag/Rij rats is
about the background level, and 1 to 2 log higher in those
of the Brown Norway rats. Our interpretation is that a sig-
nificant proportion of the vector escapes into the circula-
tion and reaches the liver and spleen, because the L44
tumour cells are poorly infected by the adenovirus. These
observations were corroborated by the results of the intra-
tumoral injection of the β-Galactosidase encoding adeno-
virus. Histological examination, 2 days after
administration of 1010iu Ad Adapt LacZ, showed that the
L42 tumour preparations were almost completely blue
whereas the L44 tumours showed few blue cells around
the needle track (Fig 2). This inhomogeneous distribution
is not specific for the L44 tumour, as it was also observed
in the L42 tumours when injecting a lower dose of virus
(data not shown).
In vitro activity of mhATF-BPTI and hEndostatin
To assess the functionality of the vectors, the biological ac-
tivities of the encoded transgenes were tested in vitro. As
depicted in Fig 3A, the mhATF-BPTI expressed in the su-
pernatant of Ad Adapt mhAB infected A459 cells was able
to inhibit 70% of the plasmin activity at a picomolar con-
centration (mol wt: 25 kD). Furthermore, mhATF-BPTI
was shown to inhibit plasmin activity at the cell surface of
rat aortic smooth muscle cells (RASMC) expressing rat
urokinase receptor [21].
The biologic activity of the endostatin encoded in the ad-
enoviral vector was determined through the bFGF simu-
lated HUVEC proliferation assay. A linear dose response
relationship between endostatin concentration and per-
centage of inhibition of HUVEC proliferation could be
demonstrated (Fig. 3B). The ED50 of endostatin (1000 ng
/ ml) was in the range of published data [25]. Further, the
angiostatic and antitumoral activities of the human en-
dostatin has been demonstrated in different rat models
[26–28].
Secretion of mhATF-BPTI and hEndostatin in animals
Brown Norway rats were injected intravenously with dif-
ferent doses of Ad Adapt mhAB (from 108 to1010iu) and
the concentration of mhATF-BPTI was assessed in the
plasma at various time points post-infection. The detec-
tion limits of the ELISA in plasma is around 5 ng / ml. The
results, depicted in Fig 4, show a linear dose response with
a maximum level of 500–800 ng / ml obtained when
1010iu Ad Adapt mhAB was injected intravenously. A lin-
ear dose response relationship was also observed in both
rat strains after iv injection of graded doses (109iu to
1010iu) of vectors encoding the marker genes luciferase
and LacZ (data not shown). In the Wag/Rij rats the plasma
levels of mhATF-BPTI were 10 times lower (Fig. 5A) after
the same vector dose. The plateau concentration after in-
travenous injection of 1010iu Ad Adapt mhAB was around
50 ng /ml plasma. In both rat strains the plasma levels
reached a plateau after 3 days and remained constant for
at least 1 month. The levels of ATF in the plasma were sim-
ilar to those of the ATF-BPTI in the Brown Norway as well
as in the Wag/Rij rats (Fig. 5B).
The human Endostatin was measured in the plasma of an-
imals that received 1010iu Ad Adapt hEndostatin intrave-
nously (Fig. 5C). The concentrations of endostatin were
much higher than those of mhATF-BPTI. The levels
reached a plateau around 10 µg / ml in the Brown Norway
rats and around 1 µg / ml in the Wag/Rij rats. Otherwise
the kinetics were roughly similar to those of mhATF-BPTI,
with a plateau lasting for a month and one log lower levels
in the Wag/Rij than in the Brown Norway rats.
Table 1: Doubling time and vascularisation of the tumours
NL 4 4  adenocarcinoma L42 squamous cell carcinoma
Rat strain Brown Norway Wag/Rij
Volume Doubling time
• in vitro [hours] 4 19.3 ± 1.9 46.2 ± 5.7
• subcutaneous tumour [days] 10 3.5 ± 0.5 8 ± 0.7
• lung metastasis [days] 10 3.9 ± 0.3 9.9 ± 0.7
MVD [%] ± SD
• subcutaneous tumour 5 3.5 ± 0.1 2 ± 0.1
The in vitro doubling time is determined after two days of culture of 106 cells / well in a 6-wells plate. The Volume Doubling Time of subcutaneous 
tumours is assessed between 1000 and 2000 mm3. For the lung metastasis the doubling time was determined between day 11 and 22 for the L44 
and between day 20 and 53 for the L42 carcinoma. The micro-vascular density (MVD) represents the surface of all endothelial cells as percentage of 
the surface of non-necrotic tissue. This was measured in 10 × 10 × 10 mm subcutaneous tumours. The values indicate means ± SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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Effects of systemic administration of Ad mhAB on tumour 
growth
The purpose of these experiments was to investigate the
response to angiostatic gene therapy of the two selected
lung tumours with different characteristics. Firstly, we in-
vestigated the effects of systemic delivery of mhATF-BPTI
on the growth of subcutaneous tumour implants.
Brown Norway rats bearing L44 tumours were treated
with intravenous injections of Ad Adapt mhATF-BPTI dai-
ly for 4 consecutive days. As depicted in Fig 6, three differ-
Figure 1
Tumour permissiveness to recombinant adenovirus. A: Luci-
ferase activity in the L42 (circles) and L44 (diamonds) cell
lines infected with increasing amounts of Ad Adapt Luc. Val-
ues are the mean of duplicate experiments. B: Luciferase
expression in subcutaneous L44 tumours (black bars) and in
L42 tumours (striped bars) after intratumoral injection of
1010iu Ad Adapt Luc. The luciferase was determined 2 days
after virus injection. Four tumours per group, vertical lines
indicate SD.
Figure 2
Distribution of adenoviral infection in the tumours. Histolog-
ical sections (magnification × 50) of L42 (above) and L44
(below) tumours stained for β-galactosidase (blue). The
necropsy was performed 2 days after intra tumoral injection
of 1010iu Ad Adapt LacZ, when the tumours were about 10
× 10 × 10 mm.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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ent doses of vector were compared and a significant
inhibition of the tumour growth (p < 0.001, ANOVA) was
observed with the 2 highest doses (109iu and 2.5 109iu).
Seven days after the viral injection, the plasma concentra-
tions of mhATF-BPTI were about 120 ng / ml and 250 ng
/ ml respectively, which is slightly higher than the levels
obtained after a single injection. In contrast, treatment of
such tumours with a low dose of adenoviral vector
(108iu), that induced lower plasma levels of mhATF-BPTI
of 10 ng / ml, did not significantly inhibit tumour growth.
Thus it appears that the anti tumour activity of mhATF-
BPTI is dependant on its systemic concentration. Higher
doses could not be achieved without inducing unaccepta-
ble liver toxicity, as manifested by a severe inflammatory
infiltrate and vacuolisation of the hepatocytes. Therefore
1010iu was the maximal accepted dose for these experi-
ments.
In a second experiment Ad Adapt mhAB and Ad Adapt
hEndostatin were compared (Fig. 7). L44 tumour pieces
were implanted subcutaneously on day 0 and 1010iu of
each vector were injected iv in a single dose on day 20. The
treatment with Ad Adapt mhAB caused a significant inhi-
bition (p < 0.0001, ANOVA) of the growth of the L44 tu-
mours as compared to the Ad Adapt empty or Ad Adapt
mhATF treated animals (Fig. 7A). The human endostatin,
which plasma level was around 10 µg / ml 2 days after vec-
tor injection, showed a slight but not significant effect (p
= 0.007, ANOVA) on tumour growth compared to the
empty vector. The mhATF-BPTI effect was achieved with a
plasma level of mhATF-BPTI of about 800 ng / ml be-
tween day 5 and 30 after the virus injection. It is required
by Dutch law to sacrifice animals when the tumour vol-
ume has surpassed 20 ml. That intervention precluded the
continuation of the growth curves after the time point at
which the first animal is sacrificed. Therefore the animals
with a tumours volume under 20 ml were plotted on a Ka-
plan Meier analysis graph. The result showed a significant
(p < 0,0001, rank test) improvement in time to sacrifice
showing an Ad Adapt mhAB specific protective effect. In
the control group, the rats (n = 9) reached the limiting size
after 38 to 50 days, whereas in the Ad AB treated group (n
Figure 3
Biological activity of the encoded proteins. A: Inhibition of
the plasmin activity (arbitrary units) by increasing amount of
mhATF-BPTI in supernatant of A459 cells infected by Ad
Adapt mhAB (black bars) or Ad Adapt Empty (white bar).
Values are means of triplicate experiments. Vertical lines
indicate SD. B: In vitro assay for endostatin activity. Inhibition
of bFGF (1 ng / ml) induced proliferation of HUVEC cells by
increasing amounts of hEndostatin in supernatant of A459
cells infected by Ad Adapt hEndo (stripped bars). Ad Adapt
Empty infection medium was used as positive control (open
bar). Values are means of quadruplicate experiments. Vertical
lines indicate SD.
Figure 4
Plasma levels of mhATF-BPTI in Brown Norway rats. The
rats received an iv injection of 1010iu (circles), 2.5109iu (tri-
angles), 109iu (squares), and 108iu (diamonds). Five animals
per group, vertical lines indicate SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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= 9), the rats had tumours above 20 ml after 55 to108
days. Mean time to sacrifice was prolonged by 30 days
(Fig. 7B).
To complete the study, the same treatment protocol was
applied to Wag/Rij rats bearing the slowly growing and
poorly vascularised L42 adenocarcinoma. A single dose of
1010iu of the different vectors was injected iv on day 14
(Fig. 7C). The plateau concentration of mhATF, mhATF-
BPTI and endostatin were low, around 50 ng/ml for the 2
first and around 0.5 µg/ml for the last respectively. No sig-
nificant inhibition of the tumour growth was observed in
either the mhATF-BPTI, the mhATF, or the endostatin
groups as compared to the empty vector group. We con-
cluded that the plasma levels of our therapeutic agents
were too low to induce any response in this model. In an
attempt to improve this issue we studied direct injection
of our vectors into the tumour.
Intra-tumoral Ad Adapt mhAB administration delays tu-
mour growth in L42
Adenoviral-mediated delivery of the mhATF-BPTI directly
at the tumour site was studied in the L42 lung carcinoma
implanted subcutaneously into Wag/Rij rats. 19 days after
implantation, one intratumoral virus injection (1010iu in
0.1 ml PBS) per day for 3 consecutive days was performed
and tumour growth monitored. Seven days after the be-
ginning of the treatment, a significant (p < 0.0001, ANO-
VA) delay of tumour growth was seen in the Ad Adapt
Figure 5
Plasma levels of the encoded proteins in Brown Norway
(squares) and Wag/Rij (circles) rats. The rats received an iv
injection of 1010iu of the respective vector on day 0. Ten ani-
mals per group, vertical lines indicate SD. A: mhATF-BPTI. B:
mhATF. C: human Endostatin. These concentrations were
reproducible in other experiments.
Figure 6
L44 tumour responses to a dose escalation of Ad Adapt
mhATF-BPTI. The animals were treated with daily iv injec-
tions of the vector for 4 consecutive days. The treatment
began 20 days after the tumour implantation when the
tumours were 8 × 8 × 8 mm. Arrows indicate days of injec-
tion. The doses employed are 108iu (open triangles, n = 4),
109iu (open circles, n = 4), and 2.5 109iu (open squares, n =
6) Ad Adapt mhATF-BPTI and 1010iu (closed squares, n = 6)
Ad Adapt empty. Vertical lines indicate SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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Figure 7
Tumour response after systemic treatment with a single iv
dose of 1010iu of the various vectors. The vectors employed
are: Ad Adapt mhATF-BPTI (open circles), Ad Adapt hEn-
dostatin (open squares), Ad Adapt mhATF (open triangles),
and Ad Adapt empty (closed squares). 10 animals per group,
vertical lines indicate SD. The arrow indicates the time of
treatment. A: L44 tumours treated by Ad Adapt mhAB (p <
0.0001, ANOVA), Ad Adapt mhATF (p = 0.03, ANOVA),
and Ad Adapt hEndo treatment (p = 0.007, ANOVA). The
treatment began at day 20 when the tumours were 8 × 8 × 8
× m. B: Kaplan-Meyer plots of treated rats: end point tumour
volume 20,000 mm3 (for the Ad Adapt mhAB, p < 0.0001,
rank test). C: L42 tumour growth curves, the viruses were
injected on day 14 when the tumours were 4 × 4 × 4 mm.
Figure 8
Tumour response after local injection of 3 consecutive doses
of 1010iu. A: L42 tumour treated with Ad Adapt mhATF-
BPTI (open circles, p < 0.0001 ANOVA), Ad Adapt mhATF
(open triangles), and Ad Adapt empty (closed squares).
Arrows indicate the days of injection (19 – 21) and the
tumours were 8 × 8 × 8 mm at the first day of injection. 10
animals per group, vertical lines indicate SD. B: L44 tumour
after treatment with 1010iu Ad Adapt mhATF-BPTI (open
circles), Ad Adapt mhATF (open squares), Ad Adapt hEn-
dostatin (open squares), and Ad Adapt empty (closed
squares). Arrows indicate the days of injection (19 – 21) and
the tumours were 8 × 8 × 8 mm at the first day of injection.
5 animals per group, vertical lines indicate SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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mhAB injected group (Fig. 8A). The mhATF-BPTI plasma
levels were under the detection limit of the ELISA.
In contrast, local delivery of the vector to the very low per-
missive L44 tumour did not lead to any significant tu-
mour growth inhibition by Ad Adapt mhAB (Fig. 8B).
Local concentration of mhATF-BPTI
The results of the systemic administration in the Brown
Norway suggested a correlation between the plasma con-
centration of mhATF-BPTI and the tumour response. The
concentrations of mhATF-BPTI were measured in the plas-
ma and in the tumour at 7 and 14 days after intravenous
or intra-tumoral injection of the mhATF-BPTI vector (Ta-
ble 2). The systemic delivery of 1010iu Ad Adapt mhAB in
L44 bearing Brown Norway rats resulted in a concentra-
tion of mhATF-BPTI in the tumour of about 1.2–1.8 µg /
g tumour. This intra-tumoral level was maintained for at
least 2 weeks and is 2–3 times higher than the plasma lev-
el. This suggests that mhATF-BPTI concentrates in the tu-
mour. The concentration of mhATF-BPTI in the L42
tumours after intravenous delivery of the vector was much
lower around 150 – 160 ng / g tumour, but as in the
Brown Norway rats 2–3 time higher than the plasma con-
centration.
The local delivery of the transgene in the tumour resulted
in a low concentration of ATF-BPTI in the L44 tumour (60
– 90 ng / g tumour) and high concentration in the L42 tu-
mours (1 – 1.4 µg / g tumour). This was expected from the
2 log higher permissiveness to adenoviral infection of the
L42 compared to the L44 tumours.
Effect of mhATF-BPTI on lung metastasis
In the subcutaneous tumour model, the majority of the
tumour cells implanted die, and the surviving cells grow
in the fibrous interstitial tissue of the skin. The subsequent
angiogenesis give rise to one small artery that will vascu-
larise the whole tumour. This probably does not reflect ac-
curately the clinical situation, where a primary carcinoma
cell grows in a highly vascularised epithelium. The angio-
genesis in non-small-cell lung carcinomas in patients
shows four different patterns of vascularisation: basal, dif-
fuse, papillary and alveolar [29]. The basal and the diffuse
are the most frequent patterns found in squamous carci-
nomas and adenocarcinomas respectively. Both are ac-
companied by a destruction of the normal lung
parenchyma and the production of newly formed vessels.
Our lung metastasis models in the rat also represent these
two main patterns: the L44 (adenocarcinoma) shows a
diffuse architecture and the L42 (squamous cell carcino-
ma) grows with a basal histological architecture. Further
characterisation showed that the growth rate of the lung
Table 2: Concentration of mhATF-BPTI in the subcutaneous tumours
L44 L42
Route of administration n Day 7 Day 14 Day 7 Day 14
Intravenous [ng / g tumour] 6 1791 ± 274 1256 ± 187 162 ± 98 152 ± 34
[ng / ml plasma] (658 ± 56) (506 ± 62) (52 ± 23) (61 ± 21)
Intratumoral [ng / g tumour] 6 59 ± 35 88 ± 34 1415 ± 147 1048 ± 485
[ng / ml plasma] ----
The concentrations were determined after a single iv injection of 1010iu Ad Adapt mhAB and after intratumoral injection of Ad Adapt mhAB (1010iu 
/ day for 3 days). The concentration of mhATF-BPTI [ng / g of fresh tissue] was determined in the tumour lysate at 7 and 14 days after the vector 
delivery. The plasma concentration [ng / ml] is indicated under the intra tumoral values. In case of the intra tumoral administration the plasma levels 
were under the detection limit.
Table 3: Concentration of mhATF-BPTI in the lung
N Brown Norway (L44) Wag/Rij (L42)
mhATF-BPTI [ng / g] animals with metastasis 7 164 ± 39 547 ± 90
mhATF-BPTI [ng / g] healthy animals 3 142 ± 51 479 ± 64
The concentration of mhATF-BPTI [ng / g of tissue] was determined at 7 days after a single intravenous injection of 1010iu Ad Adapt mhAB in 
healthy animals and in rats with lung metastasis. The values indicate means ± SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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metastases is roughly similar to that of subcutaneous im-
plants, the difference between L42 and L44 being main-
tained at both locations (Table 1).
The protective effect of systemic administration of Ad
Adapt mhAB was assessed by treating the animals with a
single iv dose of Ad Adapt mhAB, or Ad Adapt hEndosta-
tin, or with Ad Adapt Empty as negative control virus. The
treatment was administered when the micro metastasis
were a few hundreds cells large as observed in not-treated
rats. This size was reached at 4 days after injection of the
L44 tumour cells and after 13 days in the L42 model. The
animals were sacrificed when the lung nodules were ex-
pected to be 2 mm diameter in the control group. As de-
picted in Fig. 9A the L42 metastasis-bearing rats
responded to treatment with Ad Adapt mhAB with a more
than 50% reduction in the number of metastases. Macro-
scopic inspection of the lung surface and microscopic ex-
amination of lung sections gave similar responses. It is
also noteworthy that treatment with the endostatin vec-
tor, which results in a much higher level of the angiostatic
protein (1–3 µg / ml), does not significantly reduce the
number of metastases. In contrast, the L44 lung metastasis
were not significantly influenced by either the Ad Adapt
mhATF-BPTI or the Ad Adapt mhATF treatments (Fig 9B).
Surprisingly, the systemic administration of Ad Adapt
mhATF-BPTI does inhibit the growth of L42 lung metas-
tases, but not of the L44 metastases. In view of the high
permissiveness of the L42 tumour cells, it seemed possible
that the lung metastases were transfected with the mhATF-
BPTI gene. Therefore the permissiveness of the lung mi-
crometastasis was estimated, by determining the β-galac-
tosidase and luciferase activity 2 and 7 days after the iv
injection of 1010iu Ad Adapt LacZ or Ad Adapt Luc into
animals bearing L44 or L42 micrometastasis in the lungs.
The results were however essentially negative. The luci-
ferase activity was under the background level in all cases
and the sections of the frozen lungs showed no tumour
cell stained for the β-galactosidase in either L44 or L42
metastasis bearing animals (data not shown, 6 animals
per group). Thus, it seems that the metastases are not ac-
tively contributing to the levels of mhATF-BPTI in the
lungs and the concentration in the metastases should be
similar to the concentration in the lung parenchyma (all
the blood being washed out). Therefore, the concentra-
tion of mhATF-BPTI in the lung of the two rat strains was
determined. The results depicted on Table 3 show that the
mhATF-BPTI concentration is significantly higher (p <
0.001, Scheffe's test) in the Wag/Rij rats than in the Brown
Norway rats and is not influenced by the presence of me-
tastasis. The Wag/Rij rats concentrate the mhATF-BPTI in
the lung parenchyma about 10 fold, reaching therapeutic
levels. In contrast, the same systemic treatment has no ef-
fect on the L42 tumour growing subcutaneously, and this
can be explained by the fact that tumour does not concen-
trate the mhATF-BPTI sufficiently.
Influence of the tumour mass on the anti tumour activity 
of mhATF-BPTI
Radio- and chemotherapy are usually expected to be less
effective on large tumour mass than on small tumours. In
contrast, it was shown that certain anti-angiogenic com-
pounds (e.g. Combrestatin) act the other way around,
namely that they are more active on large tumours (>10
cm3) than on small tumours (<1 cm3). The supposed ex-
planation of this peculiar volume – response relationship
Figure 9
Effect of systemic treatment with 1010iu adenovirus on lung
metastasis. A: L42 metastases. The lungs were analysed 53
days after the tumour cell injection (p < 0.0001, Scheffe's test
for difference between mhAB and empty group). 10 animals
per group, vertical lines indicate SD. B: L44 metastases. The
lungs were analysed 22 days after the tumour cell injec-
tion.10 animals per group, vertical lines indicate SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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is based on the concept that the requirement for new ves-
sels increases with the size of the tumour [30]. Neverthe-
less, this is not a general rule for angiostatics. Various
compounds such as endostatin, metallo proteinase
(MMP) inhibitors, and TNP-470 do not inhibit the tu-
mour growth when its size is too large. Thus, large tu-
mours that are richly vascularised might be more sensitive
to angiostatic therapy. In order to investigate this issue in
the case of ATF-BPTI, two subcutaneous tumours with dif-
ference vascular density were treated at different time
points (figure 10 and 11). In the highly vascularised L44
as well as in the poorly vascularised CC531 tumours, ATF-
BPTI could significantly inhibit the growth of the tumours
when they were around 100 mm3 at the time of treat-
ment. In contrast, when the tumours reached a volume of
1000 mm3, the treatment had no more influence on the
tumour growth. The receptor of ATF-BPTI (uPAR) is
known to be principally present at the outer edge of the
tumour mass and as the volume increases, the proportion
of uPAR in the tumour will decrease. Thus, it was expected
that large tumour mass were insensitive to the treatment.
In this extent, ATF-BPTI is similar to the MMPs inhibitors,
in that their best indication would probably be for treat-
ment of residual disease or small metastases.
Discussion
Agents that inhibit the growth of new vessels in the tu-
mours include a wide range of different compounds. Most
of them are not toxic for endothelial cells, but impair the
dynamic process of cell proliferation, migration and ma-
trix remodelling. Thus, these agents are mostly effective
on the formation of new vessels and not on the pre-exist-
ing vasculature. Accordingly such therapy is not expected
to cause a dramatic shrinkage of an established tumour. It
appears from the different clinical trials with endostatin,
thalidomide, the synthetic inhibitors of MMPs, and the
different anti-VEGFs that angiostatics, though slightly ef-
fective in advanced diseases, are more likely indicated in
combination with chemotherapy or radiotherapy and as
an adjuvant therapy to treat small tumour masses, in par-
ticular local minimal residual disease or micrometastasis.
In whatever situation, long term systemic delivery is con-
sidered to be the treatment of choice. Therefore gene
transfer may offer an advantage. The potential of adenovi-
rus based vectors to infect the liver cells after intravenous
injection makes them suitable vectors for establishing a
prolonged systemic delivery of the encoded protein. How-
ever, our findings so far show that the achievable plasma
levels of mhATF-BPTI are limited by adenoviral damage to
the liver. To circumvent this limitation, direct injection of
the vector in the tumour was employed in an attempt to
achieve higher intra tumoral levels of the therapeutic pro-
tein.
High levels of mhATF-BPTI were achieved in the permis-
sive L42 tumour by local delivery of the vector and subse-
quently a significant inhibition of tumour growth was
obtained. The Wag/Rij rat liver is poorly permissive to the
adenoviral infection and accordingly systemic administra-
tion of the vector induces low plasma levels of mhATF-
BPTI (<80 ng / ml). Consequently, the intra tumoral con-
centration, though 3 times higher than the plasma levels,
Figure 10
Influence of the tumour mass on the anti tumour effect of
ATF-BPTI in the L44 model. The animals were treated when
the tumours were about 100 mm3 (A) or about 1000 mm3
(B). The lung adenocarcinoma L44 was implanted subcutane-
ously in Brown Norway rats and in order to achieve thera-
peutic levels, the animals were treated by intravenous
injection of the vector (1010 iu Ad Adapt mhAB or Ad Adapt
empty). The p value between the treated group and the con-
trol is indicated in the figure when the difference was signifi-
cant according to the ANOVA test. The number of animals
per group is indicated in the figures. Vertical lines indicate
SD.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/17
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was not high enough to inhibit its growth. In contrast, the
L42 lung metastasis in the Wag/Rij did respond to the in-
travenous administration of the vector encoding mhATF-
BPTI, though the resulting plasma level was low. It was
observed that the mhATF-BPTI accumulated in the lung
parenchyma, independently of the presence of metastasis,
up to a concentration of about 500 ng / g. This fully ex-
plains the therapeutic response observed in this lung me-
tastasis model.
In contrast, the L44 adenocarcinoma cells have a low per-
missiveness to the adenovirus. Consequently, in case of
direct intra tumoral delivery of the vector, the tumour
concentrations reached were low (<90 ng / g) and tumour
responses were not observed. However, the Brown Nor-
way rat liver is 10 times more permissive to the adenovirus
and produced high levels of the vector-encoded protein.
Additionally, the tumour tissue concentrates 2 to 3 fold
the mhATF-BPTI from the plasma, resulting in high intra
tumoral levels. Using graded doses of Ad Adapt mhAB, a
linear relation was observed between the dose and the
plasma level as well as between the dose and the tumour
growth delay. It appeared that a significant tumour re-
sponse could be obtained when the intra tumoral concen-
tration of mhATF-BPTI was above 400 ng / g of tissue. In
contrast, at the same plasma levels that inhibited the
growth of the subcutaneous L44 could not induce any re-
sponse on the metastasis in the lungs. The tissue concen-
tration of mhATF-BPTI in the lung of the Brown Norway
rats was apparently too low (<180 ng / g) for eliciting a de-
crease in the number of metastasis.
Conclusion
The tumour growth inhibition in both poorly and highly
vascularised L44 and L42 tumours was achieved only
when the concentration of mhATF-BPTI in the tumoral
mass or in the surrounding tissue reached a value of at
least 300 to 400 ng / g. In contrast, mhATF and the human
endostatin even at higher molecular plasma concentra-
tion than the mhATF-BPTI did not achieve any significant
inhibition of tumour growth as in established subcutane-
ous tumours as well as in micrometastasis in the lungs.
Other investigators reported that at those concentrations
endostatin and ATF induced responses of tumours and
metastases in mice [31,32]. The absence of a response in
our tumour model might be due to a lower sensitivity to
angiostatic agents. In that case our results suggest that
ATF-BPTI is a more potent agent than endostatin or ATF.
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Figure 11
Influence of the tumour mass on the anti tumour effect of
ATF-BPTI in the CC531model. The animals were treated
when the tumours were about 100 mm3 (C) or about 1000
mm3 (D). The colon adenocarcinoma CC531 grows in Wag /
Rij rats in which high plasma levels could not be obtain,
therefore the animals were treated by one intratumoral
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